Examining Analgesic Synergy and Efficacy in Trauma Care
NCT07435077 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 282
Last updated 2026-03-27
Summary
Traumatic injury is responsible for over 25 million (16%) Emergency Department visits and over 225,000 deaths each year per 2021 Center for Disease Control data. This is the 3rd leading cause of death in the US. Often, acute care for the injured patient requires administration of pain medication for the purposes of acute pain control from injury. The mainstay of treatment for pain control has historically involved opioid pain medication.
Conditions
Interventions
- DRUG
-
Buprenorphine
2 mg every 6 hours prn for moderate to severe pain If after 2 doses this is insufficient, switch to 4 mg Q6 hours as needed IV buprenorphine 150 mcg Q6 hours for breakthrough pain
- DRUG
-
Oxycodone
1000 mg acetaminophen every 6 hours (unless \<60 kg = 15 mg/kg Q6 hours) IV ketorolac 15 mg Q6 hours x 48 hours; Celebrex 200 mg twice a day after 500 mg methocarbamol three times a day If fail conservative study regimens after 24 hours, may switch to a PCA or consider other analgesic regimens (ketamine, epidural, etcetera)
Sponsors & Collaborators
-
Wake Forest University Health Sciences
lead OTHER
Principal Investigators
-
Matthew Painter, MD, FACS · Wake Forest University Health Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-31
- Primary Completion
- 2026-09-30
- Completion
- 2026-09-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Buprenorphine-Fentanyl Interaction Study
NCT03747341 ·Status: COMPLETED ·Phase: PHASE1
-
Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users
NCT00158236 ·Status: COMPLETED ·Phase: NA
-
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers
NCT01148537 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours
NCT03770234 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
NCT00134914 ·Status: COMPLETED ·Phase: NA
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
NCT05450718 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
NCT05307458 ·Status: UNKNOWN
-
Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use
NCT03266445 ·Status: UNKNOWN ·Phase: PHASE4
-
Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1
NCT00078130 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Pharmacodynamics of Buprenorphine in Healthy Volunteers
NCT00347815 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
NCT05011266 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
NCT00134888 ·Status: COMPLETED ·Phase: NA
-
Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids
NCT00218101 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine's Dose Response Curve
NCT00460239 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Treatment for Opioid Dependence
NCT02187198 ·Status: COMPLETED ·Phase: PHASE3
-
Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals
NCT02136784 ·Status: UNKNOWN ·Phase: NA
-
Buprenorphine in the Emergency Department
NCT03174067 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
NCT03015246 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
NCT05988710 ·Status: RECRUITING ·Phase: PHASE4
-
Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation.
NCT01008072 ·Status: UNKNOWN
-
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
NCT05118204 ·Status: TERMINATED ·Phase: PHASE4
-
Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients
NCT01841931 ·Status: TERMINATED ·Phase: PHASE4
-
Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms
NCT04091009 ·Status: WITHDRAWN ·Phase: PHASE4
-
Alternate-Day Buprenorphine Administration. Phase IV - 5
NCT00000223 ·Status: COMPLETED ·Phase: PHASE2
-
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
NCT02662153 ·Status: COMPLETED